

Listing of Claims:

Claims 1-20 (Canceled)

21.(Currently Amended) A method of accelerating the clearance of a polyethylene glycol-containing compound in the blood circulation of a patient who was previously administered with said polyethylene glycol-containing compound that is capable of binding to an anti-polyethylene glycol monoclonal antibody that is produced by immunizing a mouse with a RH1-βG-PEG conjugate, comprising the step of administering to said patient a pharmaceutical composition comprising ~~an~~ the anti-polyethylene glycol monoclonal antibody.

22. (Original) The method of claim 21, wherein said anti-polyethylene glycol antibody is administered to said patient less than 10 days after administering said polyethylene glycol-containing compound to said patient.

23. (Original) The method of claim 21, wherein said anti-polyethylene glycol antibody is administered to said patient less than 5 days after administering said polyethylene glycol-containing compound to said patient.

24. (Original) The method of claim 21, wherein said anti-polyethylene glycol antibody is administered to said patient from 24 hours to 5 days after administering said polyethylene glycol-containing compound to said patient.

25. (Original) The method of claim 21, wherein said polyethylene glycol-containing compound comprising β-glucuronidase.

26. (Cancelled)

27. (Previously Amended) The method of claim 21, wherein said monoclonal antibody is an IgM.

28. (Original) The method of claim 21, wherein said anti-polyethylene glycol antibody is conjugated to galactose so as to be targeted by an asialoglycoprotein receptor on a hepatocyte and uptaken by said hepatocyte.

29. (Currently Amended) A method of treating a patient suffering from a tumor, comprising the steps of:

a) administering to said patient a polyethylene glycol-containing compound that is capable of binding to an anti-polyethylene glycol monoclonal antibody that is produced by immunizing a mouse with a RH1- β G-PEG conjugate, wherein said polyethylene glycol-containing compound comprises ~~comprising~~ a tumor targeting moiety and a moiety for activating an anti-tumor prodrug ~~to said patient~~;

b) administering an anti-polyethylene glycol monoclonal antibody that is produced by immunizing a mouse with a RH1- β G-PEG conjugate to said patient to accelerate the clearance of said polyethylene glycol-containing compound from the blood circulation of said patient after step a; and

c) administering said anti-tumor prodrug to said patient after step b.

30. (Original) The method of claim 29, wherein said anti-polyethylene glycol antibody is administered to said patient less than 10 days after administering said polyethylene glycol-containing conjugate to said patient.

31. (Original) The method of claim 29, wherein said anti-polyethylene glycol antibody is administered to said patient less than 5 days after administering said polyethylene glycol-containing conjugate to said patient.

32. (Original) The method of claim 29, wherein said anti-polyethylene glycol antibody is administered to said patient from 24 hours to 5 days after administering said polyethylene glycol-containing conjugate to said patient.

33. (Previously Amended). The method of claim 29, wherein said moiety for activating an anti-tumor prodrug is β -glucuronidase.

34. (Cancelled)

35. (Previously Amended). The method of claim 29, wherein said monoclonal antibody is an IgM.

36. (Original) The method of claim 29, wherein said anti-polyethylene glycol antibody is conjugated to galactose so as to be targeted by an asialoglycoprotein receptor on a hepatocyte and uptaken by said hepatocyte.

37. (Original) The method of claim 29, wherein said anti-tumor prodrug is tetra n-butyl ammonium salt of a glucuronide derivative of p-hydroxyaniline mustard.

38. (Previously Presented) The method of claim 21, wherein said anti-polyethylene glycol monoclonal antibody is produced by a hybridoma having deposit number CCTCC-V-200001.

39. (Previously Presented) The method of claim 29, wherein said anti-polyethylene glycol monoclonal antibody is produced by a hybridoma having deposit number CCTCC-V-200001.